<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. __2__)
ADAC LABORATORIES
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
005313-10-1
________________________________
(CUSIP Number)
<TABLE>
<S> <C>
Kriston D. Qualls, Esq.
Graven Perry Block Brody & Qualls (213) 680-9770
523 West Sixth Street, Suite 1130, Los Angeles, California 90014
- -----------------------------------------------------------------
</TABLE>
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
January 23, 1996
---------------------------------------
(Date of Event which Requires Filing
of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.
Check the following box if a fee is being paid with the statement / /.
(A fee is not required only if the filing person: (1) has
a previous statement on file reporting beneficial ownership of more than five
percent of the class of securities described in Item 1; and (2) has filed no
amendment subsequent thereto reporting beneficial ownership of five percent or
less of such class.) (See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are to
be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
(Continued on following page(s))
Page 1 of 5 Pages
<PAGE> 2
CUSIP No. 005313-10-1 13D Page 2 of 5 Pages
<TABLE>
<S> <C> <C>
1 NAME OF REPORTING PERSON
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
MICHAEL O. PRELETZ (S.S. NO. ###-##-####)
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
NOT APPLICABLE (a) / /
---
(b) / /
---
3 SEC USE ONLY
4 SOURCE OF FUNDS*
PF
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) / /
---
6 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.A.
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 852,332 (4.9%)
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING -0-
PERSON
WITH 9 SOLE DISPOSITIVE POWER
852,332 (4.9%)
10 SHARED DISPOSITIVE POWER
-0-
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
852,332 (4.9%)
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / /
---
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.9%
14 TYPE OF REPORTING PERSON*
IN
</TABLE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE> 3
ADAC LABORATORIES
AMENDMENT NO. 2 TO SCHEDULE 13D
FILED BY
MICHAEL O. PRELETZ
This Amendment No. 2 to Schedule 13D is being filed to reflect
Mr. Preletz' ownership of securities of ADAC Laboratories has fallen below 5%
as a result of ADAC having 17,139,545 outstanding shares of Common Stock as of
December 1, 1995, as reported in its Form 10-K for the period ended October 1,
1995.
ITEM 1 SECURITY AND ISSUER.
The title of the class of equity securities to which this
Statement relates is Common Stock, no par value. The name, address and
telephone number of the Issuer of such securities is:
ADAC Laboratories
540 Alder Drive
Milpitas, California 95035
(408) 321-9100
ITEM 2. IDENTITY AND BACKGROUND.
The following information is given with respect to the person
filing this Statement.
(a) Name: Michael O. Preletz
(b) Business Address: 1334 Park View Avenue, Suite 245
Manhattan Beach, CA 90266
(c) Principal Occupation:
(i) Consultant and strategic advisor to various companies.
(d) Inapplicable.
(e) Inapplicable.
(f) Citizenship: United States.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
The source of funds used by Mr. Preletz to directly or
indirectly acquire his current holdings of shares of ADAC Laboratories was from
personal funds.
<PAGE> 4
Amendment No. 2 to Schedule 13D
ADAC Laboratories, by
Michael O. Preletz
Page 4
ITEM 4. PURPOSE OF THE TRANSACTION.
Mr. Preletz has previously purchased shares of ADAC
Laboratories for investment purposes only. Mr. Preletz has not acquired any
shares of ADAC Laboratories since December 12, 1991.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
(a) and (b) As of the date hereof, Mr. Preletz may be deemed
to be the beneficial owner (with sole voting and dispositive power) of 852,332
Common Shares (4.9%) of ADAC Laboratories. The percentage stated is based upon
17,139,545 shares of Common Stock of the Issuer issued and outstanding as of
December 1, 1995.
(c) Mr. Preletz has not effected any transactions in the
securities of ADAC Laboratories during the past sixty (60) days.
(d) Inapplicable.
(e) Based upon the number of outstanding shares (17,139,545)
of ADAC Laboratories as of December 1, 1995, as set forth in its Form 10-K
Annual Report for the period ended October 1, 1995, Mr. Preletz holds less
than 5% of this class of securities.
ITEM 6. CONTRACTS, ARRANGEMENTS AND UNDERSTANDINGS.
Inapplicable.
ITEM 7. MATERIALS TO BE FILED AS EXHIBITS.
Inapplicable.
4
<PAGE> 5
Amendment No. 2 to Schedule 13D
ADAC Laboratories, by
Michael O. Preletz
Page 5
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this Statement is true, complete and
correct.
DATED: January 23, 1996
/s/ Michael O. Preletz
------------------------------
Michael O. Preletz
5
